What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 4

High volatility and concerns regarding product side effects.

Up 8% but noted for high volatility and concerns regarding product side effects.

Considered 'dirt cheap' with a strong Rule of 40 score of 48 and defensive growth qualities decoupled from macro tensions.

Part of the expanded IA13 basket of high-growth AI-related companies.

Stock is down and speaker questions the long-term impact of product side effects.

Significant disconnect between fundamental performance and share price; 100,000 monthly weight loss subscriptions could add $210M in ARR not yet priced in.

The CFO's plan to sell 75% of his personal shareholdings and concerns over product concentration in hair loss treatments suggest a lack of executive confidence and high risk.

Shifting to a comprehensive healthcare disruptor using a 'loss-leader' strategy with lab screenings and proprietary EHR to capture long-term customers in weight loss and longevity.

Transitioning from a D2C provider to a healthcare disruptor by verticalizing infrastructure, including pharmacy fulfillment and diagnostics, while scaling GLP-1 accessibility.

Current price is a disconnect from strong fundamentals; company has a 95% recurring revenue model and is expanding into peptide manufacturing.

May benefit from compounded GLP-1 versions, but analysts are skeptical of long-term moat.

Significant price drop is viewed as nonsensical relative to strong company performance; seen as an opportunity.

Noted for its pivot into the GLP-1 weight loss space and ownership of its entire supply chain.

The speaker views the recent pullback to $19 as a major buying opportunity, citing strong recurring revenue, expansion into GLP-1s and peptides, and a valuation of 2x forward gross profit.

Experienced a massive 10% drop, described as 'carnage'.

Significant disconnect between perfect business execution and a 70% stock decline; viewed as a contrarian opportunity due to fundamental undervaluation.

Current price drops are viewed as nonsensical and driven by market fear rather than fundamentals, representing a potential contrarian opportunity.

Major legal risks have been resolved and new branded GLP-1 product launches with Novo Nordisk provide a massive growth catalyst not yet reflected in guidance.

Positive momentum from expansion into peptides and weight-loss treatments leveraging its customer database.

Deeply undervalued at $21 as legal risks and regulatory overhangs from Novo Nordisk and the FDA have been resolved; positioned for growth through peptide partnerships.

Positioned as the 'McDonald's of Peptides' to bring anti-aging and GLP-1 treatments to the mass market.

Viewed as a high-conviction play with favorable risk-reward despite sector volatility.

Used as a comparison for stocks where price response does not match the quality of news.

Strategic pivot into the peptide and GLP-1 weight-loss space with a vertically integrated supply chain advantage.

Bear thesis dismantled after Novo Nordisk partnership and FDA support; stock is irrationally priced near bear-market lows despite reduced legal risk.

Showing strength with a 5% price increase amid broader market volatility.

Strong Rule of 40 score of 60 with underpriced growth; bear thesis on GLP-1 lawsuits was invalidated by Novo Nordisk partnership.

Viewed as a resilient subscription model for 'must-have' pills; current price drop is seen as an unfair result of basket selling rather than poor fundamentals.

Considered undervalued relative to growth despite a recent rally; legal overhang regarding GLP-1 drugs has largely dissipated.

Currently caught in a rally of high-risk 'animal spirit' assets.

Showing idiosyncratic strength, up double digits despite broader market weakness.

Upgraded by Bank of America following resolution of Novo Nordisk conflicts; high volatility and short squeeze potential.

Surged 40% after Novo Nordisk dropped its lawsuit; high short interest could lead to a squeeze to $30.

Showing idiosyncratic strength and high growth, up 42% regardless of the macro environment.

Significant de-risking following a partnership with Novo Nordisk for Wegovy; stock viewed as undervalued with potential for 35% to 45% annual growth.

Surged 50% after a lawsuit dismissal; potential for partnership in GLP-1 distribution and short squeeze potential.

Significant trend reversal and green momentum following a partnership announcement, decoupling from the broader market.

Strategic partnership with Novo Nordisk to sell branded GLP-1 products and potential for an epic short squeeze due to high short interest and improving fundamentals.

Used as a proxy for the high-growth sector; represents a recovery opportunity if interest rates return to zero.

Market is currently treating it as a pure GLP-1 play, ignoring other fundamentals; potential for 3x returns for those who can withstand 60% drawdowns.

Viewed as undervalued with strong revenue growth projected at 24-33% for 2026 including the Eucalyptus acquisition; strong competitive moat via physical medical networks.

Preferred as a more stable alternative in the Direct-to-Consumer space compared to Oddity Tech.

The speaker is extremely bullish, believing the market is misinterpreting guidance and that the long-term thesis is a bet on the company becoming a dominant AI-driven healthcare platform.

Stock dropped over 10% due to a significant growth slowdown, low subscriber growth, and the disclosure of an SEC investigation.

Despite beating current estimates, the company's guidance for a sharp deceleration in revenue growth (from 60% to 23%) and weak subscriber growth were major red flags.

The speaker is extremely bullish, viewing the stock as 'way undervalued' and a 'long-term hold' due to its hyper-growth, vertical integration, and improving profitability, believing the market is misunderstanding the company.

Used as an example of a high-growth stock that is down significantly (70%) due to a broad, indiscriminate market sell-off, rather than company-specific issues.

Mentioned as a comparable growth stock that also experienced a significant sell-off from its highs, similar to Klarna.

The stock is down approximately 80% from its highs, and the head of compliance has recently left the company, which is considered a major red flag. This combination of poor stock performance and executive departure signals significant risk, potential governance issues, and has led to a deep lack of trust and highly bearish sentiment.

The stock is mentioned as an example of a delta-neutral trade (buying convertible bonds while shorting the stock) by professionals. This is not an endorsement but an illustration of a market environment that is dangerous for retail investors.